Acasti Pharma Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $22.29 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Acasti Pharma Inc had its IPO on 2011-05-06 under the ticker symbol ACST.
The company operates in the Healthcare sector and Biotechnology industry. Acasti Pharma Inc has a staff strength of 0 employees.
Shares of Acasti Pharma Inc opened at $0.44 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $0.43 - $0.46, and closed at $0.44.
This is a -4.35% slip from the previous day's closing price.
A total volume of 34,800 shares were traded at the close of the day’s session.
In the last one week, shares of Acasti Pharma Inc have slipped by -6.38%.
Acasti Pharma Inc's Key Ratios
Acasti Pharma Inc has a market cap of $22.29 million, indicating a price to book ratio of 0.1573 and a price to sales ratio of 208.3872.
In the last 12-months Acasti Pharma Inc’s revenue was $115000 with a gross profit of $120000 and an EBITDA of $-14938000. The EBITDA ratio measures Acasti Pharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Acasti Pharma Inc’s operating margin was 0% while its return on assets stood at -8.27% with a return of equity of -16.6%.
In Q4, Acasti Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Acasti Pharma Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.33 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Acasti Pharma Inc’s profitability.
Acasti Pharma Inc stock is trading at a EV to sales ratio of 5.5008 and a EV to EBITDA ratio of 1.037. Its price to sales ratio in the trailing 12-months stood at 208.3872.
Acasti Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $116.80 million
- Total Liabilities
- $3.43 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Acasti Pharma Inc ended 2023 with $116.80 million in total assets and $0 in total liabilities. Its intangible assets were valued at $116.80 million while shareholder equity stood at $96.72 million.
Acasti Pharma Inc ended 2023 with $0 in deferred long-term liabilities, $3.43 million in other current liabilities, 258294000.00 in common stock, $-169179000.00 in retained earnings and $12.96 million in goodwill. Its cash balance stood at $26.24 million and cash and short-term investments were $31.26 million. The company’s total short-term debt was $73,000 while long-term debt stood at $0.
Acasti Pharma Inc’s total current assets stands at $33.43 million while long-term investments were $0 and short-term investments were $5.02 million. Its net receivables were $778000.00 compared to accounts payable of $3.36 million and inventory worth $0.
In 2023, Acasti Pharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Acasti Pharma Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Acasti Pharma Inc stock is currently trading at $0.44 per share. It touched a 52-week high of $1.35 and a 52-week low of $1.35. Analysts tracking the stock have a 12-month average target price of $2.25.
Its 50-day moving average was $0.63 and 200-day moving average was $0.68 The short ratio stood at 1.73 indicating a short percent outstanding of 0%.
Around 2028.4% of the company’s stock are held by insiders while 11.3% are held by institutions.
Frequently Asked Questions About Acasti Pharma Inc
Similar Industry Stocks (Biotechnology)
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.